Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
-0.73% $6.80
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 720.03 mill |
EPS: | -1.420 |
P/E: | -4.79 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 105.89 mill |
Avg Daily Volume: | 2.22 mill |
RATING 2024-03-28 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Strong Sell | |
P/E: | Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -4.79 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.81x |
Company: PE -4.79 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$1.197 (-82.40%) $-5.60 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 6.11 - 7.49 ( +/- 10.10%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-14 | Shendelman Shoshana | Sell | 318 573 | Common Stock |
2024-03-14 | Perfetti Riccardo | Sell | 110 804 | Common Stock |
2024-03-14 | Hansard Adam | Sell | 48 871 | Common Stock |
2024-03-14 | Funtleyder Leslie D. | Sell | 28 727 | Common Stock |
2023-12-28 | Chinoporos Constantine | Buy | 300 000 | Common Stock |
INSIDER POWER |
---|
42.68 |
Last 98 transactions |
Buy: 24 718 894 | Sell: 4 549 161 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $6.80 (-0.73% ) |
Volume | 1.435 mill |
Avg. Vol. | 2.22 mill |
% of Avg. Vol | 64.77 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $2.71 | N/A | Active |
---|
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.